Plexus Corp. (NASDAQ: PLXS) today announced financial results for
our fiscal first quarter ended December 28, 2024, and guidance
for our fiscal second quarter ending March 29, 2025.
- Reports fiscal first quarter 2025
revenue of $976 million, GAAP operating margin of 4.8% and GAAP
diluted EPS of $1.34.
- Reports fiscal first quarter 2025
non-GAAP operating margin of 6.0% and non-GAAP diluted EPS of
$1.73, excluding $0.24 of stock-based compensation expense and
$0.15 of restructuring and other charges, net of tax.
- Initiates fiscal second quarter
2025 revenue guidance of $960 million to $1.00 billion with GAAP
diluted EPS of $1.22 to $1.37, including $0.24 of stock-based
compensation expense. Fiscal second quarter non-GAAP EPS guidance
of $1.46 to $1.61 excludes stock-based compensation expense.
|
|
|
Three Months Ended |
|
Dec 28, 2024 |
|
Dec 28, 2024 |
|
Mar 29, 2025 |
|
Q1F25 Results |
|
Q1F25 Guidance |
|
Q2F25 Guidance |
Summary GAAP Items |
|
|
|
|
|
|
Revenue (in millions) |
$976 |
|
|
$960 to $1,000 |
|
$960 to $1,000 |
Operating margin |
4.8 |
% |
|
4.9% to 5.3% |
|
4.6% to 5.0% |
Diluted EPS |
$1.34 |
|
|
$1.25 to $1.40 |
|
$1.22 to $1.37 |
|
|
|
|
|
|
|
Summary Non-GAAP Items (1) |
|
|
|
|
|
|
Adjusted operating margin (2) |
6.0 |
% |
|
5.7% to 6.1% |
|
5.3% to 5.7% |
Adjusted EPS (3) |
$1.73 |
|
|
$1.52 to $1.67 |
|
$1.46 to $1.61 |
Return on invested capital (ROIC) |
13.8 |
% |
|
|
|
|
Economic return |
4.9 |
% |
|
|
|
|
(1) |
Refer to Non-GAAP Supplemental Information tables for additional
information regarding non-GAAP financial measures. |
(2) |
Excludes stock-based compensation expense of approximately 70 bps
for Q1F25 results, 50 bps for Q1F25 guidance and 70 bps for Q2F25
guidance. Excludes restructuring charges of approximately 50 bps
for Q1F25 results and 30 bps for Q1F25 guidance. |
(3) |
Excludes stock-based compensation expense, net of tax, of $0.24 for
Q1F25 results, $0.19 for Q1F25 guidance and $0.24 for Q2F25
guidance. Excludes restructuring charges, net of tax, of $0.15 for
Q1F25 results and $0.08 for Q1F25 guidance. |
|
|
Fiscal First
Quarter 2025
Information
- Won 30 manufacturing programs
during the quarter representing $212 million in annualized revenue
when fully ramped into production.
- Generated fiscal first quarter free cash flow of $27
million.
- Purchased $12.8 million of our
shares at an average price of $151.19 per share under our 2025
Share Repurchase Program, leaving $37.2 million available under our
existing $50.0 million authorization.
Todd Kelsey, President and Chief Executive
Officer, commented, "Our team's agility and responsiveness enabled
strong operating performance in the fiscal first quarter, resulting
in robust financial results to begin fiscal 2025. We delivered
fiscal first quarter revenue of $976 million, in-line with
expectations, and non-GAAP operating margin of 6.0%, near the high
end of our guidance and consistent with our long-term goal. This
contributed to non-GAAP EPS of $1.73, which exceeded guidance.
Furthermore, free cash flow generation surpassed expectations,
benefiting from the ongoing efforts of our fiscal 2024 initiatives
to drive sustained improvement in working capital efficiency."
Patrick Jermain, Executive Vice President and
Chief Financial Officer, commented, "Aided by a cash cycle of 68
days, 5 days favorable to expectations, we delivered our best
fiscal first quarter free cash flow performance in five years,
generating $27 million. The ongoing improvements in our cash cycle
also continue to benefit return on invested capital, which was
13.8% for the fiscal first quarter, or 490 basis points above our
weighted average cost of capital. Although net working capital
investments in support of program ramps are anticipated for the
fiscal second quarter, our robust fiscal first quarter free cash
generation positions us to now deliver up to $100 million of free
cash for fiscal 2025. Finally, reinforcing our commitment to create
additional shareholder value, we reduced our borrowing by $37
million and repurchased $13 million of our shares during the fiscal
first quarter."
Mr. Kelsey continued, "We delivered 30 fiscal
first quarter manufacturing wins, representing $212 million in
annualized revenue. The wins performance reflects continued strong
contribution within our Healthcare/Life Sciences market sector as
well as exciting growth opportunities within our Aerospace/Defense
and Industrial market sectors. In addition, our engineering
solutions team delivered a win total that approached a two-year
high, while our funnel of engineering opportunities continues to
see increased diversification. We believe both are strong leading
indicators of future Plexus revenue growth."
Mr. Kelsey concluded, "Considering current market
sector dynamics and typical seasonal cost pressures, we are guiding
to fiscal second quarter revenue of $960 million to $1.00 billion,
non-GAAP operating margin of 5.3% to 5.7% and non-GAAP EPS of $1.46
to $1.61. Lastly, we remain confident in achieving meaningful EPS
growth in fiscal 2025 by leveraging revenue expansion in each of
our market sectors, ongoing strong operating margin performance and
continued deployment of our free cash flow to create additional
shareholder value."
|
|
Quarterly Comparison |
Three Months
Ended |
(in
thousands, except EPS) |
Dec 28, 2024 |
|
Sep 28, 2024 |
|
Dec 30, 2023 |
Revenue |
$ |
976,122 |
|
|
$ |
1,050,569 |
|
|
$ |
982,607 |
|
Gross
profit |
|
100,692 |
|
|
|
107,912 |
|
|
|
88,140 |
|
Operating
income |
|
46,860 |
|
|
|
53,858 |
|
|
|
45,158 |
|
Net
income |
|
37,267 |
|
|
|
41,221 |
|
|
|
29,215 |
|
Diluted
EPS |
$ |
1.34 |
|
|
$ |
1.48 |
|
|
$ |
1.04 |
|
|
|
|
|
|
|
Gross
margin |
|
10.3 |
% |
|
|
10.3 |
% |
|
|
9.0 |
% |
Operating
margin |
|
4.8 |
% |
|
|
5.1 |
% |
|
|
4.6 |
% |
|
|
|
|
|
|
ROIC
(1) |
|
13.8 |
% |
|
|
11.8 |
% |
|
|
10.3 |
% |
Economic
return (1) |
|
4.9 |
% |
|
|
3.6 |
% |
|
|
2.1 |
% |
(1) |
Refer to Non-GAAP Supplemental Information tables for non-GAAP
financial measures discussed and/or disclosed in this release, such
as adjusted operating margin, adjusted net income, adjusted diluted
EPS, ROIC and economic return. |
|
|
Business Segment and Market Sector
Revenue
Plexus measures operational performance and
allocates resources on a geographic segment basis. Plexus also
reports revenue based on the market sector breakout set forth in
the table below, which reflects Plexus’ market sector focused
strategy. Top 10 customers comprised 51% of revenue during the
first quarter of fiscal 2025. This is down 1 percentage point from
the fourth quarter of fiscal 2024 and up 3 percentage points from
the first quarter of fiscal 2024.
|
|
Business Segments ($ in millions) |
Three Months Ended |
|
Dec 28, 2024 |
|
Sep 28, 2024 |
|
Dec 30, 2023 |
Americas |
$ |
274 |
|
|
$ |
307 |
|
|
$ |
310 |
|
Asia-Pacific |
|
607 |
|
|
|
618 |
|
|
|
553 |
|
Europe, Middle East and Africa |
|
101 |
|
|
|
128 |
|
|
|
121 |
|
Elimination of inter-segment sales |
|
(6 |
) |
|
|
(2 |
) |
|
|
(1 |
) |
Total Revenue (1) |
$ |
976 |
|
|
$ |
1,051 |
|
|
$ |
983 |
|
(1) |
In the first quarter of fiscal 2025, Plexus changed its internal
management reporting to focus on value-add sales in each region and
adjusted the allocation of certain corporate costs amongst
reportable segments. These changes have been implemented and are
consistent with what is provided to the Chief Executive Officer as
our chief operating decision maker. The Company's composition of
operating segments and reportable segments did not change. Net
sales and operating income for our three reportable segments for
the current period and comparative periods presented have been
recast to conform to those changes. These changes had no effect on
the Company's consolidated net sales, operating income or net
income for the current or comparative periods. Refer to the
Supplemental Segment Information in Table 3 for the prospective
presentation of previously filed periods. |
|
|
Market Sectors ($ in millions) |
Three Months Ended |
|
Dec 28, 2024 |
|
Sep 28, 2024 |
|
Dec 30, 2023 |
Aerospace/Defense |
$ |
160 |
16 |
% |
|
$ |
184 |
18 |
% |
|
$ |
167 |
17 |
% |
Healthcare/Life Sciences |
|
374 |
38 |
% |
|
|
415 |
39 |
% |
|
|
381 |
39 |
% |
Industrial |
|
442 |
46 |
% |
|
|
452 |
43 |
% |
|
|
435 |
44 |
% |
Total Revenue |
$ |
976 |
|
|
$ |
1,051 |
|
|
$ |
983 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Supplemental
Information
Plexus provides non-GAAP supplemental
information, such as ROIC, economic return and free cash flow,
because such measures are used for internal management goals and
decision-making, and because they provide management and investors
with additional insight into financial performance. In addition,
management uses these and other non-GAAP measures, such as adjusted
operating income, adjusted operating margin, adjusted net income
and adjusted diluted EPS, to provide a better understanding of core
performance for purposes of period-to-period comparisons. Plexus
believes that these measures are also useful to investors because
they provide further insight by eliminating the effect of
non-recurring items that are not reflective of continuing
operations. For additional information on non-GAAP measures, please
refer to the attached Non-GAAP Supplemental Information tables.
ROIC and Economic Return
ROIC for the first quarter of fiscal 2025 was
13.8%. Plexus defines ROIC as tax-effected annualized adjusted
operating income divided by average invested capital over a
two-quarter period for the first fiscal quarter. Invested capital
is defined as equity plus debt and operating lease obligations,
less cash and cash equivalents. Plexus' weighted average cost of
capital for fiscal 2025 is 8.9%. ROIC for the first quarter of
fiscal 2025 less Plexus’ weighted average cost of capital resulted
in an economic return of 4.9%.
Free Cash Flow
Plexus defines free cash flow as cash flows
provided by operations less capital expenditures. For the three
months ended December 28, 2024, cash flows provided by
operations was $53.6 million, less capital expenditures of $26.5
million, resulting in free cash flow of $27.1 million.
|
|
Cash Cycle Days |
Three Months Ended |
|
Dec 28, 2024 |
|
Sep 28, 2024 |
|
Dec 30, 2023 |
Days in Accounts Receivable |
56 |
|
|
54 |
|
|
61 |
|
Days in Contract Assets |
12 |
|
|
10 |
|
|
12 |
|
Days in Inventory |
134 |
|
|
127 |
|
|
161 |
|
Days in Accounts Payable |
(69 |
) |
|
(59 |
) |
|
(66 |
) |
Days in Advanced Payments |
(65 |
) |
|
(68 |
) |
|
(73 |
) |
Annualized Cash Cycle (1) |
68 |
|
|
64 |
|
|
95 |
|
(1) |
Plexus calculates cash cycle as the sum of days in accounts
receivable, days in contract assets and days in inventory, less
days in accounts payable and days in advanced payments. |
|
|
Conference Call and Webcast
Information
What: |
Plexus Fiscal 2025 Q1 Earnings Conference Call and Webcast |
When: |
Thursday, January 23, 2025 at 8:30 a.m. Eastern Time |
Where: |
Participants are encouraged to join the live webcast at the
investor relations section of the Plexus website,
plexus.com. Participants can also join utilizing the links
below: Webcast
link: https://events.q4inc.com/attendee/140961572 |
Replay: |
The webcast will be archived on the Plexus website and will be
available as on-demand for 12 months |
|
|
Investor and Media Contact
Shawn Harrison +1.920.969.6325 shawn.harrison@plexus.com
About Plexus Since 1979, Plexus
has helped create the products that build a better world. Driven by
a passion for excellence, we partner with our customers to design,
manufacture and service highly complex products in demanding
regulatory environments. From life-saving medical devices and
mission-critical aerospace and defense products to industrial
automation systems and semiconductor capital equipment, our
innovative solutions across the lifecycle of a product converge
where advanced technology and human impact intersect. We provide
these solutions to market-leading as well as disruptive global
companies in the Aerospace/Defense, Healthcare/Life Sciences, and
Industrial sectors, supported by a global team of over 20,000
members across our 26 facilities in the Americas ("AMER"),
Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA")
regions. For more information about Plexus, visit our website at
www.plexus.com.
Safe Harbor and Fair Disclosure
Statement The statements contained in this press release
that are guidance or which are not historical facts (such as
statements in the future tense and statements including believe,
expect, intend, plan, anticipate, goal, target and similar terms
and concepts), including all discussions of periods which are not
yet completed, are forward-looking statements that involve risks
and uncertainties. These risks and uncertainties include the effect
of inflationary pressures on our costs of production,
profitability, and on the economic outlook of our markets; the
effects of shortages and delays in obtaining components as a result
of economic cycles, natural disasters or otherwise; the risk of
customer delays, changes, cancellations or forecast inaccuracies in
both ongoing and new programs; the ability to realize anticipated
savings from restructuring or similar actions, as well as the
adequacy of related charges as compared to actual expenses; the
lack of visibility of future orders, particularly in view of
changing economic conditions; the economic performance of the
industries, sectors and customers we serve; the outcome of
litigation and regulatory investigations and proceedings, including
the results of any challenges with regard to such outcomes; the
effects of tariffs, trade disputes, trade agreements and other
trade protection measures; the effects of the volume of revenue
from certain sectors or programs on our margins in particular
periods; our ability to secure new customers, maintain our current
customer base and deliver product on a timely basis; the risks of
concentration of work for certain customers; the particular risks
relative to new or recent customers, programs or services, which
risks include customer and other delays, start-up costs, potential
inability to execute, the establishment of appropriate terms of
agreements, and the lack of a track record of order volume and
timing; the effects of start-up costs of new programs and
facilities or the costs associated with the closure or
consolidation of facilities; possible unexpected costs and
operating disruption in transitioning programs, including
transitions between Company facilities; the risk that new program
wins and/or customer demand may not result in the expected revenue
or profitability; the fact that customer orders may not lead to
long-term relationships; our ability to manage successfully and
execute a complex business model characterized by high product mix
and demanding quality, regulatory, and other requirements; the
risks associated with excess and obsolete inventory, including the
risk that inventory purchased on behalf of our customers may not be
consumed or otherwise paid for by the customer, resulting in an
inventory write-off; risks related to information technology
systems and data security; increasing regulatory and compliance
requirements; any tax law changes and related foreign jurisdiction
tax developments; current or potential future barriers to the
repatriation of funds that are currently held outside of the United
States as a result of actions taken by other countries or
otherwise; the potential effects of jurisdictional results on our
taxes, tax rates, and our ability to use deferred tax assets and
net operating losses; the weakness of areas of the global economy;
the effect of changes in the pricing and margins of products; raw
materials and component cost fluctuations; the potential effect of
fluctuations in the value of the currencies in which we transact
business; the effects of changes in economic conditions, political
conditions and regulatory matters in the United States and in the
other countries in which we do business; the potential effect of
other world or local events or other events outside our control
(such as the conflict between Russia and Ukraine, conflict in the
Middle East, escalating tensions between China and Taiwan or China
and the United States, changes in energy prices, terrorism, global
health epidemics and weather events); the impact of increased
competition; an inability to successfully manage human capital;
changes in financial accounting standards; and other risks detailed
herein and in our other Securities and Exchange Commission filings,
particularly in Risk Factors contained in our fiscal 2024 Form
10-K.
|
PLEXUS CORP. AND SUBSIDIARIES |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share data) |
(unaudited) |
|
|
|
Three Months Ended |
|
Dec 28, |
|
Dec 30, |
|
2024 |
|
2023 |
Net sales |
$ |
976,122 |
|
|
$ |
982,607 |
|
Cost of sales |
|
875,430 |
|
|
|
894,467 |
|
Gross profit |
|
100,692 |
|
|
|
88,140 |
|
Operating expenses: |
|
|
|
Selling and administrative expenses |
|
49,149 |
|
|
|
42,982 |
|
Restructuring and other charges |
|
4,683 |
|
|
|
— |
|
Operating income |
|
46,860 |
|
|
|
45,158 |
|
Other income (expense): |
|
|
|
Interest expense |
|
(3,554 |
) |
|
|
(7,617 |
) |
Interest income |
|
1,234 |
|
|
|
808 |
|
Miscellaneous, net |
|
(1,046 |
) |
|
|
(3,502 |
) |
Income before income taxes |
|
43,494 |
|
|
|
34,847 |
|
Income tax expense |
|
6,227 |
|
|
|
5,632 |
|
Net income |
$ |
37,267 |
|
|
$ |
29,215 |
|
Earnings per share: |
|
|
|
Basic |
$ |
1.38 |
|
|
$ |
1.06 |
|
Diluted |
$ |
1.34 |
|
|
$ |
1.04 |
|
Weighted average shares outstanding: |
|
|
|
Basic |
|
27,087 |
|
|
|
27,485 |
|
Diluted |
|
27,763 |
|
|
|
28,013 |
|
|
|
|
|
|
|
|
|
PLEXUS CORP. AND SUBSIDIARIES |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(in thousands, except per share data) |
(unaudited) |
|
Dec 28, |
|
Sep 28, |
|
2024 |
|
2024 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
317,161 |
|
|
$ |
345,109 |
|
Restricted cash |
|
688 |
|
|
|
2,353 |
|
Accounts receivable |
|
597,470 |
|
|
|
622,366 |
|
Contract assets |
|
128,086 |
|
|
|
120,560 |
|
Inventories |
|
1,290,179 |
|
|
|
1,311,434 |
|
Prepaid expenses and other |
|
53,739 |
|
|
|
75,328 |
|
Total current assets |
|
2,387,323 |
|
|
|
2,477,150 |
|
Property, plant and equipment, net |
|
505,108 |
|
|
|
501,112 |
|
Operating lease right-of-use assets |
|
78,045 |
|
|
|
74,360 |
|
Deferred income taxes |
|
73,832 |
|
|
|
73,919 |
|
Other assets |
|
27,009 |
|
|
|
27,280 |
|
Total non-current assets |
|
683,994 |
|
|
|
676,671 |
|
Total assets |
$ |
3,071,317 |
|
|
$ |
3,153,821 |
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Current portion of long-term debt and finance lease
obligations |
$ |
121,977 |
|
|
$ |
157,325 |
|
Accounts payable |
|
666,118 |
|
|
|
606,378 |
|
Advanced payments from customers |
|
625,315 |
|
|
|
709,152 |
|
Accrued salaries and wages |
|
78,458 |
|
|
|
94,448 |
|
Other accrued liabilities |
|
73,507 |
|
|
|
75,991 |
|
Total current liabilities |
|
1,565,375 |
|
|
|
1,643,294 |
|
Long-term debt and finance lease obligations, net of current
portion |
|
88,728 |
|
|
|
89,993 |
|
Accrued income taxes payable |
|
17,198 |
|
|
|
17,198 |
|
Long-term operating lease liabilities |
|
35,124 |
|
|
|
32,275 |
|
Deferred income taxes |
|
7,233 |
|
|
|
8,234 |
|
Other liabilities |
|
38,590 |
|
|
|
38,002 |
|
Total non-current liabilities |
|
186,873 |
|
|
|
185,702 |
|
Total liabilities |
|
1,752,248 |
|
|
|
1,828,996 |
|
Shareholders’ equity: |
|
|
|
Common stock |
|
545 |
|
|
|
545 |
|
Additional paid-in-capital |
|
684,555 |
|
|
|
680,638 |
|
Common stock held in treasury |
|
(1,202,939 |
) |
|
|
(1,190,115 |
) |
Retained earnings |
|
1,860,410 |
|
|
|
1,823,143 |
|
Accumulated other comprehensive (loss) income |
|
(23,502 |
) |
|
|
10,614 |
|
Total shareholders’ equity |
|
1,319,069 |
|
|
|
1,324,825 |
|
Total liabilities and shareholders’ equity |
$ |
3,071,317 |
|
|
$ |
3,153,821 |
|
|
|
|
|
PLEXUS CORP. AND SUBSIDIARIES |
NON-GAAP SUPPLEMENTAL INFORMATION Table 1 |
(in thousands, except per share data) |
(unaudited) |
|
|
|
|
|
|
|
Three Months Ended |
|
Dec 28, |
|
Sep 28, |
|
Dec 30, |
|
2024 |
|
2024 |
|
2023 |
Operating income, as reported |
$ |
46,860 |
|
|
$ |
53,858 |
|
|
$ |
45,158 |
|
Operating margin, as reported |
|
4.8 |
% |
|
|
5.1 |
% |
|
|
4.6 |
% |
|
|
|
|
|
|
Non-GAAP adjustments: |
|
|
|
|
|
Restructuring and other charges (1) |
|
4,683 |
|
|
|
— |
|
|
|
— |
|
Stock-based compensation |
|
6,990 |
|
|
|
10,849 |
|
|
|
5,335 |
|
Non-GAAP operating income |
$ |
58,533 |
|
|
$ |
64,707 |
|
|
$ |
50,493 |
|
Non-GAAP operating margin |
|
6.0 |
% |
|
|
6.2 |
% |
|
|
5.1 |
% |
|
|
|
|
|
|
Net income, as reported |
$ |
37,267 |
|
|
$ |
41,221 |
|
|
$ |
29,215 |
|
|
|
|
|
|
|
Non-GAAP adjustments: |
|
|
|
|
|
Restructuring and other charges, net of tax (1) |
|
4,191 |
|
|
|
— |
|
|
|
— |
|
Stock-based compensation, net of tax |
|
6,640 |
|
|
|
10,306 |
|
|
|
5,335 |
|
Adjusted net income |
$ |
48,098 |
|
|
$ |
51,527 |
|
|
$ |
34,550 |
|
|
|
|
|
|
|
Diluted earnings per share, as reported |
$ |
1.34 |
|
|
$ |
1.48 |
|
|
$ |
1.04 |
|
|
|
|
|
|
|
Non-GAAP per share adjustments: |
|
|
|
|
|
Restructuring and other charges, net of tax (1) |
|
0.15 |
|
|
|
— |
|
|
|
— |
|
Stock-based compensation, net of tax |
|
0.24 |
|
|
|
0.37 |
|
|
|
0.19 |
|
Adjusted diluted earnings per share |
$ |
1.73 |
|
|
$ |
1.85 |
|
|
$ |
1.23 |
|
(1) |
During the three months ended December 28, 2024, restructuring
costs of $4.7 million, or $4.2 million net of taxes, were incurred
primarily for employee severance costs associated with a reduction
in the Company's workforce in the EMEA and AMER regions. |
|
|
PLEXUS CORP. AND SUBSIDIARIES |
NON-GAAP SUPPLEMENTAL INFORMATION Table 2 |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
ROIC and Economic Return Calculations |
Three Months Ended |
|
Twelve Months Ended |
|
Three Months Ended |
|
Dec 28, |
|
Sep 28, |
|
Dec 30, |
|
2024 |
|
2024 |
|
2023 |
Operating income, as reported |
|
$ |
46,860 |
|
|
|
$ |
167,732 |
|
|
|
$ |
45,158 |
|
Restructuring and other charges, net |
|
|
4,683 |
|
|
|
|
20,257 |
|
|
|
|
— |
|
Accelerated stock-based compensation (1) |
+ |
|
— |
|
|
+ |
|
5,063 |
|
|
+ |
|
— |
|
Adjusted operating income |
|
$ |
51,543 |
|
|
|
$ |
193,052 |
|
|
|
$ |
45,158 |
|
|
x |
|
4 |
|
|
|
|
|
x |
|
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted annualized operating income |
|
$ |
206,172 |
|
|
|
$ |
193,052 |
|
|
|
$ |
180,632 |
|
Adjusted effective tax rate |
x |
|
15 |
% |
|
x |
|
13 |
% |
|
x |
|
16 |
% |
Tax impact |
|
|
30,926 |
|
|
|
|
25,097 |
|
|
|
|
28,901 |
|
Adjusted operating income (tax-effected) |
|
$ |
175,246 |
|
|
|
$ |
167,955 |
|
|
|
$ |
151,731 |
|
|
|
|
|
|
|
|
|
|
Average invested capital |
÷ |
$ |
1,268,309 |
|
|
÷ |
$ |
1,418,698 |
|
|
÷ |
$ |
1,479,647 |
|
ROIC |
|
|
13.8 |
% |
|
|
|
11.8 |
% |
|
|
|
10.3 |
% |
Weighted average cost of capital |
- |
|
8.9 |
% |
|
- |
|
8.2 |
% |
|
- |
|
8.2 |
% |
Economic return |
|
|
4.9 |
% |
|
|
|
3.6 |
% |
|
|
|
2.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average Invested Capital Calculations |
Dec 28, |
|
Sep 28, |
|
Jun 29, |
|
Mar 30, |
|
Dec 30, |
|
Sep 30, |
|
2024 |
|
2024 |
|
2024 |
|
2024 |
|
2023 |
|
2023 |
Equity |
$ |
1,319,069 |
|
|
$ |
1,324,825 |
|
|
$ |
1,266,360 |
|
|
$ |
1,259,762 |
|
|
$ |
1,266,755 |
|
|
$ |
1,214,382 |
|
Plus: |
|
|
|
|
|
|
|
|
|
|
|
Debt and finance lease obligations - current |
|
121,977 |
|
|
|
157,325 |
|
|
|
258,175 |
|
|
|
245,964 |
|
|
|
251,119 |
|
|
|
240,205 |
|
Operating lease obligations - current (2) |
|
14,875 |
|
|
|
14,697 |
|
|
|
7,990 |
|
|
|
8,281 |
|
|
|
9,172 |
|
|
|
8,363 |
|
Debt and finance lease obligations - long-term |
|
88,728 |
|
|
|
89,993 |
|
|
|
90,715 |
|
|
|
192,025 |
|
|
|
192,118 |
|
|
|
190,853 |
|
Operating lease obligations - long-term |
|
35,124 |
|
|
|
32,275 |
|
|
|
31,923 |
|
|
|
33,915 |
|
|
|
35,989 |
|
|
|
38,552 |
|
Less: Cash and cash equivalents |
|
(317,161 |
) |
|
|
(345,109 |
) |
|
|
(269,868 |
) |
|
|
(265,053 |
) |
|
|
(231,982 |
) |
|
|
(256,233 |
) |
|
$ |
1,262,612 |
|
|
$ |
1,274,006 |
|
|
$ |
1,385,295 |
|
|
$ |
1,474,894 |
|
|
$ |
1,523,171 |
|
|
$ |
1,436,122 |
|
(1) |
During the twelve months ended September 28, 2024, $5.1 million of
accelerated stock-based compensation expense was recorded in
selling and administrative expense in the accompanying Condensed
Consolidated Statements of Operations as a result of executive
retirement agreements. |
(2) |
Included in other accrued liabilities on the Condensed Consolidated
Balance Sheets. |
|
|
PLEXUS CORP. AND SUBSIDIARIES |
SUPPLEMENTAL SEGMENT INFORMATION Table 3 |
(in thousands) |
(unaudited) |
|
|
Three Months Ended |
|
Twelve Months Ended |
|
Dec 30, |
|
Mar 30, |
|
Jun 29, |
|
Sep 28, |
|
Sep 28, |
|
Sep 30, |
|
2023 |
|
2024 |
|
2024 |
|
2024 |
|
2024 |
|
2023 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
AMER |
$ |
309,753 |
|
|
$ |
296,177 |
|
|
$ |
306,522 |
|
|
$ |
306,773 |
|
|
$ |
1,219,225 |
|
|
$ |
1,468,996 |
|
APAC |
|
552,841 |
|
|
|
521,658 |
|
|
|
520,928 |
|
|
|
617,826 |
|
|
|
2,213,253 |
|
|
|
2,361,777 |
|
EMEA |
|
121,277 |
|
|
|
152,292 |
|
|
|
136,670 |
|
|
|
127,814 |
|
|
|
538,053 |
|
|
|
402,427 |
|
Eliminations |
|
(1,264 |
) |
|
|
(3,227 |
) |
|
|
(3,369 |
) |
|
|
(1,844 |
) |
|
|
(9,704 |
) |
|
|
(22,895 |
) |
|
$ |
982,607 |
|
|
$ |
966,900 |
|
|
$ |
960,751 |
|
|
$ |
1,050,569 |
|
|
$ |
3,960,827 |
|
|
$ |
4,210,305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income: |
|
|
|
|
|
|
|
|
|
|
|
AMER |
$ |
18,950 |
|
|
$ |
15,480 |
|
|
$ |
23,964 |
|
|
$ |
25,306 |
|
|
$ |
83,700 |
|
|
$ |
123,099 |
|
APAC |
|
77,132 |
|
|
|
72,878 |
|
|
|
75,285 |
|
|
|
87,906 |
|
|
|
313,201 |
|
|
|
313,120 |
|
EMEA |
|
3,197 |
|
|
|
9,729 |
|
|
|
9,287 |
|
|
|
8,820 |
|
|
|
31,033 |
|
|
|
16,013 |
|
Corporate and other costs |
|
(54,121 |
) |
|
|
(68,617 |
) |
|
|
(69,290 |
) |
|
|
(68,174 |
) |
|
|
(260,202 |
) |
|
|
(256,412 |
) |
|
$ |
45,158 |
|
|
$ |
29,470 |
|
|
$ |
39,246 |
|
|
$ |
53,858 |
|
|
$ |
167,732 |
|
|
$ |
195,820 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plexus (NASDAQ:PLXS)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Plexus (NASDAQ:PLXS)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025